KALVISTA PHARMACEUTICALS INC (KALV) Stock Price, Quote, News and Overview
NASDAQ:KALV - Nasdaq - US4834971032 - Common Stock - Currency: USD
KALV Quote, Performance and Key Statistics
KALVISTA PHARMACEUTICALS INC
NASDAQ:KALV (1/30/2025, 1:45:30 PM)
9
+0.23 (+2.62%)
The current stock price of KALV is 9 USD. In the past month the price increased by 2.81%. In the past year, price decreased by -42.38%.
KALV Latest News, Press Releases and Analysis
KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Appoints Jeb Ledell as Chief Operating Officer
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
KALV Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.35 | 310.50B | ||
| AMGN | AMGEN INC | 14.84 | 153.33B | ||
| GILD | GILEAD SCIENCES INC | 21.82 | 120.49B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 866.39 | 113.79B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.07 | 75.23B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.77B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.70B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.63B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.30B | ||
| NTRA | NATERA INC | N/A | 23.26B | ||
| BIIB | BIOGEN INC | 9.02 | 21.45B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.51B |
Related stock screener links
About KALV
Company Profile
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The company is headquartered in Cambridge, Massachusetts and currently employs 150 full-time employees. The company went IPO on 2015-04-09. The firm is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The firm is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.
Company Info
KALVISTA PHARMACEUTICALS INC
55 Cambridge Pkwy Ste 901E
Cambridge MASSACHUSETTS 02142 US
CEO: T. Andrew Crockett
Employees: 150
Company Website: https://www.kalvista.com/
Investor Relations: https://ir.kalvista.com
Phone: 18579990075
KALV FAQ
What is the stock price of KALV?
The current stock price of KALV is 9 USD.
What is the symbol for KALVISTA PHARMACEUTICALS INC stock?
The exchange symbol of KALVISTA PHARMACEUTICALS INC is KALV and it is listed on the Nasdaq exchange.
On which exchange is KALV stock listed?
KALV stock is listed on the Nasdaq exchange.
Is KALV a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for KALV, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of KALV.
Does KALV stock pay dividends?
KALV does not pay a dividend.
What is the Price/Earnings (PE) ratio of KALV?
KALV does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.64).
What is the Short Interest ratio of KALV stock?
The outstanding short interest for KALV is 17.01% of its float.
KALV Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to KALV. When comparing the yearly performance of all stocks, KALV is a bad performer in the overall market: 91.04% of all stocks are doing better.
KALV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KALV. KALV has a great financial health rating, but its profitability evaluates not so good.
KALV Financial Highlights
Over the last trailing twelve months KALV reported a non-GAAP Earnings per Share(EPS) of -3.64. The EPS increased by -18.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -97.24% | ||
| ROE | -116.71% | ||
| Debt/Equity | 0 |
KALV Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to KALV. The Buy consensus is the average rating of analysts ratings from 14 analysts.